{"id":64699,"date":"2026-05-08T14:10:37","date_gmt":"2026-05-08T06:10:37","guid":{"rendered":"https:\/\/flcube.com\/?p=64699"},"modified":"2026-05-08T14:10:37","modified_gmt":"2026-05-08T06:10:37","slug":"jiangsu-lianhuan-pharma-reports-positive-phase-iii-results-for-lh-1801-sglt-2-inhibitor-in-type-2-diabetes-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64699","title":{"rendered":"Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment"},"content":{"rendered":"\n<p><strong>Jiangsu Lianhuan Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600513:SHA\">SHA: 600513<\/a>) announced successful unblinding of two pivotal <strong>Phase III clinical trials<\/strong> for <strong>LH-1801<\/strong>, its <strong>Class 1 novel SGLT-2 inhibitor<\/strong> co-developed with the <strong>Shanghai Institute of Materia Medica, Chinese Academy of Sciences<\/strong>. The drug demonstrated <strong>non-inferiority to dapagliflozin<\/strong> in combination therapy and <strong>superiority over placebo<\/strong> as monotherapy for <strong>type 2 diabetes (T2D)<\/strong> in Chinese adult patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-overview\">Clinical Trial Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial Design<\/th><th>Patient Population<\/th><th>Primary Endpoint<\/th><th>Key Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Combination Therapy<\/strong><\/td><td>T2D adults on metformin with inadequate glycemic control<\/td><td>HbA1c reduction vs. dapagliflozin + metformin<\/td><td><strong>Non-inferior<\/strong> to active comparator<\/td><\/tr><tr><td><strong>Monotherapy<\/strong><\/td><td>T2D adults controlled by diet\/exercise alone<\/td><td>HbA1c reduction vs. placebo<\/td><td><strong>Statistically superior<\/strong> to placebo<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-development-partnership\">Drug Profile &amp; Development Partnership<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule<\/strong>: LH-1801, novel SGLT-2 inhibitor (Class 1 innovative drug)<\/li>\n\n\n\n<li><strong>Target Indication<\/strong>: Type 2 diabetes mellitus (T2D)<\/li>\n\n\n\n<li><strong>Development Partnership<\/strong>: Co-developed with Shanghai Institute of Materia Medica, Chinese Academy of Sciences<\/li>\n\n\n\n<li><strong>Regulatory Status<\/strong>: Class 1 designation indicates first-in-class or best-in-class potential under China&#8217;s NMPA classification<\/li>\n\n\n\n<li><strong>Commercial Rights<\/strong>: Jiangsu Lianhuan holds exclusive marketing rights in Greater China; global partnership discussions ongoing<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-summary\">Clinical Evidence Summary<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-combination-therapy-trial\">Combination Therapy Trial<\/h3>\n\n\n\n<p>The Phase III study evaluating <strong>LH-1801 plus metformin<\/strong> versus <strong>dapagliflozin plus metformin<\/strong> met its primary endpoint of <strong>non-inferiority in glycemic efficacy<\/strong>. Secondary endpoints included safety profile, weight reduction, and blood pressure effects, with full data expected in Q3 2026.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-monotherapy-trial\">Monotherapy Trial<\/h3>\n\n\n\n<p>The monotherapy study demonstrated that <strong>LH-1801 as a single agent<\/strong> achieved <strong>statistically significant and clinically meaningful reductions in HbA1c<\/strong> compared to placebo in patients whose diabetes was inadequately controlled by lifestyle modifications alone.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SGLT-2 Inhibitor Market<\/strong>: Global market valued at <strong>$9.8 billion in 2025<\/strong>, projected to reach <strong>$14.2 billion by 2030<\/strong><\/li>\n\n\n\n<li><strong>China T2D Prevalence<\/strong>: Over <strong>140 million adults<\/strong> with diabetes, representing the world&#8217;s largest diabetic population<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: LH-1801 would be the <strong>fifth SGLT-2 inhibitor<\/strong> approved in China if successful, joining dapagliflozin, empagliflozin, canagliflozin, and ertugliflozin<\/li>\n\n\n\n<li><strong>Differentiation Strategy<\/strong>: Potential advantages in <strong>safety profile, dosing convenience, or cost-effectiveness<\/strong> to be detailed in complete data disclosure<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-and-commercial-outlook\">Regulatory and Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NMPA Submission Timeline<\/strong>: Marketing application expected in Q4 2026 following completion of full data analysis<\/li>\n\n\n\n<li><strong>Revenue Projections<\/strong>: Analysts estimate peak annual sales of <strong>\u00a5800 million\u2013\u00a51.2 billion<\/strong> ($110\u2013170 million) assuming 3\u20135% market share capture<\/li>\n\n\n\n<li><strong>Reimbursement Strategy<\/strong>: Target inclusion in <strong>National Reimbursement Drug List (NRDL)<\/strong> negotiations scheduled for 2027<\/li>\n\n\n\n<li><strong>Manufacturing Capacity<\/strong>: Existing production facilities capable of meeting initial demand; expansion plans contingent on approval timeline<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-implications\">Investment Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Stock Performance<\/strong>: SHA: 600513 closed at \u00a528.45 on May 7, 2026; trading volume expected to increase following announcement<\/li>\n\n\n\n<li><strong>Pipeline Valuation<\/strong>: LH-1801 represents the company&#8217;s most advanced asset; successful approval could double enterprise value<\/li>\n\n\n\n<li><strong>Partnership Opportunities<\/strong>: International pharma companies monitoring development progress for potential licensing agreements<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory submissions, and commercial projections for LH-1801. Actual outcomes may differ due to regulatory review timelines, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600513_20260508_JTLT.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600513_20260508_JTLT.\"><\/object><a id=\"wp-block-file--media-92d7f21b-76f1-4950-970c-166d8c571de5\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600513_20260508_JTLT.pdf\">600513_20260508_JTLT<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600513_20260508_JTLT.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-92d7f21b-76f1-4950-970c-166d8c571de5\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced successful unblinding of two pivotal Phase III&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,39,3245,4125],"class_list":["post-64699","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-diabetes","tag-lianhuan-pharmaceutical","tag-sha-600513"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced successful unblinding of two pivotal Phase III clinical trials for LH-1801, its Class 1 novel SGLT-2 inhibitor co-developed with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The drug demonstrated non-inferiority to dapagliflozin in combination therapy and superiority over placebo as monotherapy for type 2 diabetes (T2D) in Chinese adult patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64699\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced successful unblinding of two pivotal Phase III clinical trials for LH-1801, its Class 1 novel SGLT-2 inhibitor co-developed with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The drug demonstrated non-inferiority to dapagliflozin in combination therapy and superiority over placebo as monotherapy for type 2 diabetes (T2D) in Chinese adult patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64699\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-08T06:10:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64699#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64699\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment\",\"datePublished\":\"2026-05-08T06:10:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64699\"},\"wordCount\":485,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"Diabetes\",\"Lianhuan Pharmaceutical\",\"SHA: 600513\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64699#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64699\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64699\",\"name\":\"Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-08T06:10:37+00:00\",\"description\":\"Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced successful unblinding of two pivotal Phase III clinical trials for LH-1801, its Class 1 novel SGLT-2 inhibitor co-developed with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The drug demonstrated non-inferiority to dapagliflozin in combination therapy and superiority over placebo as monotherapy for type 2 diabetes (T2D) in Chinese adult patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64699#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64699\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64699#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced successful unblinding of two pivotal Phase III clinical trials for LH-1801, its Class 1 novel SGLT-2 inhibitor co-developed with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The drug demonstrated non-inferiority to dapagliflozin in combination therapy and superiority over placebo as monotherapy for type 2 diabetes (T2D) in Chinese adult patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64699","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment","og_description":"Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced successful unblinding of two pivotal Phase III clinical trials for LH-1801, its Class 1 novel SGLT-2 inhibitor co-developed with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The drug demonstrated non-inferiority to dapagliflozin in combination therapy and superiority over placebo as monotherapy for type 2 diabetes (T2D) in Chinese adult patients.","og_url":"https:\/\/flcube.com\/?p=64699","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-08T06:10:37+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64699#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64699"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment","datePublished":"2026-05-08T06:10:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64699"},"wordCount":485,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","Diabetes","Lianhuan Pharmaceutical","SHA: 600513"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64699#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64699","url":"https:\/\/flcube.com\/?p=64699","name":"Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-08T06:10:37+00:00","description":"Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced successful unblinding of two pivotal Phase III clinical trials for LH-1801, its Class 1 novel SGLT-2 inhibitor co-developed with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The drug demonstrated non-inferiority to dapagliflozin in combination therapy and superiority over placebo as monotherapy for type 2 diabetes (T2D) in Chinese adult patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64699#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64699"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64699#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64699"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64699\/revisions"}],"predecessor-version":[{"id":64703,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64699\/revisions\/64703"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}